| Johnson and Johnson announces study presentation at NKF meetings | Posted on 07/04/2008 in Pharmaceutical Company Product News Johnson & Johnson has announced that data from clinical studies sponsored by Ortho Biotech, its biotechnology subsidiary, are being presented at the 2008 spring meetings of the National Kidney Foundation.
It adds that three of these studies involve Procrit (epoetin alfa), including trials that compare the costs and drug utilisation patterns of the compound with darbepoetin alfa.
The trials evaluate the medical costs related to chronic kidney disease patients who also have hypertension or diabetes, while using a software-based management tool to assess the impact on haemoglobin control.
"Procrit is used for the treatment of anaemia in patients with most types of cancer receiving chemotherapy, with chronic renal failure who are on dialysis and those who are not on dialysis," the company said.
It added that the compound is also used by patients being treated with zidovudine for HIV infection and to lower the need for transfusion in anaemia patients who are scheduled noncardiac, nonvascular surgery.
Last month, Johnson and Johnson reaffirmed the safety and efficacy of erythropoiesis-stimulating agents used as a treatment for chemotherapy-induced anaemia, claiming that there is no association of on-label use of the drugs with disease progression or an increased risk of mortality.Other news stories from 07/04/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
